What question did this study set out to answer?

To evaluate the performance of subcutaneous atezolizumab in treating non-small cell lung cancer and compare it to the intravenous formulation.

April 10, 2026Therapeutic Delivery

Subcutaneous atezolizumab for the treatment of non-small cell lung cancer

View Full Paper

Ask AI

Bookmark

Authors

JGJaime González-MonteroFinis Terrae University CRCarlos I RojasFinis Terrae University MBMauricio BurottoUniversidad de Los Andes, Chile

Discussion

Member takes

Implication

This review examines subcutaneous atezolizumab's efficacy in non-small cell lung cancer, suggesting a convenient alternative to intravenous treatment.

Key Points

To evaluate the performance of subcutaneous atezolizumab in treating non-small cell lung cancer and compare it to the intravenous formulation.
Reviewed pharmacokinetic, clinical, safety, and operational data from IMscin001 and related studies.
Analyzed a fixed dose of 1,875 mg SC every 3 weeks for bioavailability and exposure.
Focused on patient-reported outcomes and time-and-motion analyses for treatment burden.
Monitored immune-related adverse events and assessed standard immunotoxicity protocols.
Subcutaneous dosing shows non-inferior bioavailability to intravenous dosing.
Response rates, progression-free survival, and overall survival are comparable across both methods.
Patients prefer subcutaneous treatment due to reduced chair time and lower treatment burden.
Injection-site reactions were mild and infrequent, with no new safety concerns.

Cite This Study

González-Montero et al. (2026) studied this question.

synapsesocial.com/papers/69d894ce6c1944d70ce05c58 https://doi.org/10.1080/20415990.2026.2655547

View Full Paper

Ask AI

Bookmark

Implication

This review examines subcutaneous atezolizumab's efficacy in non-small cell lung cancer, suggesting a convenient alternative to intravenous treatment.

Subcutaneous atezolizumab for the treatment of non-small cell lung cancer

Discussion

Member takes

Implication

Key Points

Cite This Study

Subcutaneous atezolizumab for the treatment of non-small cell lung cancer

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider